AstraZeneca And 2 More British Biotech Stocks To Watch

With UK households squeezed by higher mortgage and energy costs as interest rates climb, investors are hunting for assets that are not tied directly to everyday spending power. British biotech stocks sit in that sweet spot, where progress depends more on scientific results than on consumer budgets. This article highlights three UK biotechnology shares from a quality-focused screener that may help you build exposure to this higher risk, higher potential corner of the market.

The three stocks highlighted next are only a sample from a wider search, with the full screen surfacing 4 more biotech companies with equally compelling stories that are not covered here. To identify and analyze potential high conviction biotech opportunities with reasonable balance sheets for yourself, head straight into the Biotech Stocks screener.

AstraZeneca (LSE:AZN)

AstraZeneca is a global biopharmaceutical group built around prescription medicines, with a major focus on biotech-driven oncology drugs and complex biologics that fit cleanly with this screener’s search for higher risk, higher reward science backed by sizeable commercial franchises.

AstraZeneca generates about US$62.4b from pharmaceuticals, ranging from targeted cancer therapies to rare disease biologics, and has a market value of roughly £216.1b, which gives it far more scale than most biotech-focused peers in this screen.

For biotech investors, AstraZeneca offers something different from early stage pure plays, with a large portfolio of commercialised biologic drugs and targeted oncology therapies already helping to fund the next wave of higher risk science.

"The company's robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular or metabolic therapies, is now underpinned by management's disclosure of 12 programs each with risk adjusted peak sales potential above US$5b and several more in the US$3b to US$5b range."

What happens to future returns if a single assumption about how that late stage portfolio converts into sustainable margins and cash generation breaks?

If that assumption is what you are testing, read the full narrative for AstraZeneca to see how AstraZeneca’s pipeline, capital allocation and risk profile all connect.

Hikma Pharmaceuticals (LSE:HIK)

Hikma Pharmaceuticals gives this biotech screen a different angle, with a mix of hospital injectables, branded treatments and retail generics that keep it closer to cash generating products while still tying into oncology and other specialist therapies.

Hikma Pharmaceuticals develops generic, specialty and branded drugs across hospitals and pharmacies, with Injectables bringing in about $1.4b, Hikma Rx roughly $1.0b, Branded around $900 million and smaller revenue from Others, and the group valued at about £3.4b.

"Hikma Pharmaceuticals is materially increasing R&D investment and concentrating it through three global platforms with disciplined NPV and IRR stage gates, which aims to shift the portfolio toward fewer, higher value complex products that can support higher net margins and earnings quality over time."

What happens if one quiet constraint on that oncology and complex injectables mix keeps group profitability from fully reflecting the higher value pipeline?

If that friction point is what concerns you, read the full narrative for Hikma Pharmaceuticals to see whether Hikma’s R&D push is quietly building a higher quality earnings mix.

Genus (LSE:GNS)

Genus uses biotech style genetics to help farmers breed more productive dairy and pork herds. Genus PIC and Genus ABS together generate about £655.6 million of the £658.1 million group revenue, and the whole business is valued at roughly £1.5 billion.

Genus brings a different twist to the biotech theme. Its genomics work is focused on breeding healthier, more productive herds rather than developing human therapies. This is exactly where its animal genetics divisions start to matter for long term cash generation.

"The porcine joint venture in China with Beijing Capital Agribusiness, combined with expected proceeds of about £100m in fiscal Q4 FY26 and Genus’ current PIC market share below 5% in a country that hosts roughly half of the world’s pigs, gives the company scope to grow China related revenue and earnings over time."

The real swing factor is how one pressure on future profitability and cash conversion ultimately resolves across that genomics heavy portfolio.

That pressure point is exactly where the full narrative for Genus shows how current profitability could be masking a much bigger earnings engine.

Seeking Alternatives Before Momentum Flies

Fresh ideas often move first. Once momentum builds, prices can move fast and ideal entry points can be harder to find. Scan these curated lists before the crowd and consider your options in advance.

• Explore resilient income streams by reviewing a curated 4 dividend fortresses that focuses on holdings aimed at maintaining their payouts while weaker distributions may face pressure.
• Follow the structural shift toward automation with the carefully assembled 89 robotics and automation stocks, before interest in this theme increases around earnings headlines.
• Review potential exposure to infrastructure spending through a hand picked 42 power grid technology and infrastructure stocks connected to the modernisation of energy systems worldwide.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com